Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:OBIO NASDAQ:PROF NASDAQ:RXST NASDAQ:SEPA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeOBIOOrchestra BioMed$4.24+8.7%$4.03$2.20▼$5.42$233.54M0.5222,546 shs5.42 million shsPROFProfound Medical$6.50+2.0%$6.80$3.76▼$8.95$231.47M0.7256,266 shs13,630 shsRXSTRxSight$5.36+4.5%$5.82$4.48▼$13.65$221.89M1.14955,341 shs3.47 million shsSEPASEP Acquisition$10.32$10.19$7.86▼$17.00$59.96M0.1511,589 shsN/A7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceOBIOOrchestra BioMed+8.72%+6.27%+7.34%-0.47%+37.22%PROFProfound Medical+2.04%-5.39%-5.39%+5.01%+8.33%RXSTRxSight+4.48%+13.32%-4.63%-14.38%-59.33%SEPASEP Acquisition0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeOBIOOrchestra BioMed$4.24+8.7%$4.03$2.20▼$5.42$233.54M0.5222,546 shs5.42 million shsPROFProfound Medical$6.50+2.0%$6.80$3.76▼$8.95$231.47M0.7256,266 shs13,630 shsRXSTRxSight$5.36+4.5%$5.82$4.48▼$13.65$221.89M1.14955,341 shs3.47 million shsSEPASEP Acquisition$10.32$10.19$7.86▼$17.00$59.96M0.1511,589 shsN/A7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceOBIOOrchestra BioMed+8.72%+6.27%+7.34%-0.47%+37.22%PROFProfound Medical+2.04%-5.39%-5.39%+5.01%+8.33%RXSTRxSight+4.48%+13.32%-4.63%-14.38%-59.33%SEPASEP Acquisition0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceOBIOOrchestra BioMed 2.57Moderate Buy$13.60220.75% UpsidePROFProfound Medical 2.00Hold$12.0084.62% UpsideRXSTRxSight 1.93Reduce$9.4476.20% UpsideSEPASEP Acquisition 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest SEPA, OBIO, PROF, and RXST Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2026PROFProfound Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/11/2026RXSTRxSight Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/22/2026PROFProfound Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/22/2026RXSTRxSight Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/19/2026OBIOOrchestra BioMed B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$12.00 ➝ $10.005/14/2026OBIOOrchestra BioMed HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.005/13/2026OBIOOrchestra BioMed BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$12.00 ➝ $13.005/7/2026PROFProfound Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/7/2026RXSTRxSight Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/7/2026RXSTRxSight Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$11.00 ➝ $9.005/7/2026RXSTRxSight Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$13.00 ➝ $11.00(Data available from 6/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookOBIOOrchestra BioMed$32.72M7.76N/AN/A$0.95 per share4.46PROFProfound Medical$16.10M14.67N/AN/A$1.83 per share3.55RXSTRxSight$127.48M1.74N/AN/A$6.70 per share0.80SEPASEP AcquisitionN/AN/AN/AN/A($0.63) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateOBIOOrchestra BioMed-$52.70M-$0.97N/AN/AN/A-166.96%-157.46%-60.18%8/11/2026 (Estimated)PROFProfound Medical-$42.57M-$1.24N/AN/AN/A-206.76%-78.88%-64.06%8/13/2026 (Estimated)RXSTRxSight-$38.94M-$1.13N/AN/AN/A-36.58%-17.01%-15.12%8/6/2026 (Estimated)SEPASEP Acquisition-$2.36MN/AN/AN/AN/AN/AN/A-38.32%N/ALatest SEPA, OBIO, PROF, and RXST EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026OBIOOrchestra BioMed-$0.40-$0.33+$0.07-$0.33$0.92 million$0.11 million5/7/2026Q1 2026PROFProfound Medical-$0.24-$0.19+$0.05-$0.19$4.85 million$5.34 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthOBIOOrchestra BioMedN/AN/AN/AN/AN/APROFProfound MedicalN/AN/AN/AN/AN/ARXSTRxSightN/AN/AN/AN/AN/ASEPASEP AcquisitionN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioOBIOOrchestra BioMed0.357.037.01PROFProfound MedicalN/A6.565.71RXSTRxSightN/A10.208.93SEPASEP AcquisitionN/A0.570.57Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipOBIOOrchestra BioMed53.20%PROFProfound Medical47.86%RXSTRxSight78.78%SEPASEP Acquisition3.66%Insider OwnershipCompanyInsider OwnershipOBIOOrchestra BioMed7.50%PROFProfound Medical1.52%RXSTRxSight10.05%SEPASEP Acquisition20.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableOBIOOrchestra BioMed459.88 million55.39 millionNot OptionablePROFProfound Medical15036.34 million35.79 millionOptionableRXSTRxSight22041.40 million37.24 millionOptionableSEPASEP Acquisition25.81 million4.65 millionNot OptionableSEPA, OBIO, PROF, and RXST HeadlinesRecent News About These CompaniesNo headlines for this company have been tracked by MarketBeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesGameStop’s $2 Billion Buyback Sends a Confusing Signal to InvestorsBy Thomas Hughes | June 10, 2026Viasat's Orbiting Profits: Space Force Jackpot?By Jeffrey Neal Johnson | June 14, 2026AirJoule Technologies: A Cool Shot at a MultibaggerBy Thomas Hughes | June 9, 2026Microsoft’s Xbox Problem Is Bigger Than a Console WarBy Jeffrey Neal Johnson | June 17, 2026HubSpot Just Crushed the Bear Case—Is a Bigger Rally Ahead?By Sam Quirke | June 2, 2026SEPA, OBIO, PROF, and RXST Company DescriptionsOrchestra BioMed NASDAQ:OBIO$4.24 +0.34 (+8.72%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$4.10 -0.14 (-3.40%) As of 06/26/2026 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.Profound Medical NASDAQ:PROF$6.50 +0.13 (+2.04%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$6.56 +0.05 (+0.85%) As of 06/26/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.RxSight NASDAQ:RXST$5.36 +0.23 (+4.48%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$5.39 +0.03 (+0.49%) As of 06/26/2026 05:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.SEP Acquisition NASDAQ:SEPASEP Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. The company was formerly known as Mercury Ecommerce Acquisition Corp. and changed its name to SEP Acquisition Corp. in December 2022. The company was incorporated in 2021 and is based in Houston, Texas. SEP Acquisition Corp. is a subsidiary of Mercury Sponsor Group I LLC. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Rocket Lab's NASA Win Tests Key Support After Sharp Pullback BlackBerry’s Rally Is Running on a Bigger AI Story Than Earnings Alone Fabrinet Is Becoming a Quiet Winner in the AI Optics Buildout Palantir’s Valuation Problem Just Met 2 New Growth Catalysts Micron’s HBM Surge Could Redefine the AI Growth Story Carnival's Second Quarter: Is the Stock Still Complicated? Xcel Energy Stock Offers Stability as Electricity Demand Builds Microsoft Solves AI’s Biggest Bottleneck With Chevron Deal Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
